Lipella Pharmaceuticals announced the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus, or OLP, patients.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO: